The Hidden Tax on Your Prescriptions: What the Labor Department's PBM Disclosure Rule Actually Changes

For decades, the American pharmaceutical supply chain has operated on a principle that would be unacceptable in almost any other industry: the middlemen who negotiate drug prices on behalf of employers and health plans are not required to tell those clients how much they are keeping for themselves. That arrangement ends in July 2027, when a final rule published by the Department of Labor on October 29, 2026 takes effect. The rule requires pharmacy benefit managers to disclose, for the first time, the full scope of fees, rebates, and spread payments they collect from every corner of the drug supply chain. The reaction from employers was relief. The reaction from PBMs was fury. Both responses tell you something important about what this rule actually does.

What PBMs Do, and Why the Opacity Matters

Pharmacy benefit managers occupy a peculiar position in American healthcare. They are hired by self-insured employers and health plans to manage prescription drug benefits, negotiate discounts with manufacturers, determine which drugs appear on formularies, and process claims. The three largest, Cigna's Express Scripts, CVS's Caremark, and UnitedHealth's Optum Rx, collectively control roughly 80 percent of all U.S. prescriptions. That concentration gives them extraordinary leverage over every other participant in the drug supply chain, from manufacturers to pharmacies to the employers who pay the bills.

The problem is that PBMs have historically used that leverage in ways that are difficult for their clients to observe or verify. When a PBM negotiates a rebate from a drug manufacturer in exchange for favorable formulary placement, the employer paying for the benefit plan may not know how large that rebate is, or how much of it the PBM retains rather than passing through. When a PBM reimburses a pharmacy less for a prescription than the employer's plan paid, the employer may not know the difference exists. These arrangements, known as spread pricing, have been documented in state audits and federal investigations, but the information asymmetry between PBMs and their clients has made systematic accountability nearly impossible.

Drug costs are expected to jump 11.5 percent in 2026, up from 9 percent the year prior, according to advisory firm WTW. Employers are spending more on pharmaceuticals than ever, and fewer than half of large employers report getting sufficient insight into how their PBM is managing those dollars. The DOL rule is designed to close that gap by requiring PBMs to disclose rebate arrangements, spread payments, and other compensation when negotiating or renewing contracts, and then every six months thereafter. Employers will be able to audit the disclosures once a year. PBMs that fail to comply face financial penalties and potential contract invalidation.

Why the PBM Industry's Objections Deserve Scrutiny

The Pharmaceutical Care Management Association, the largest PBM lobby, has argued that the rule is duplicative, burdensome, and legally unnecessary given PBM reforms already enacted in the Consolidated Appropriations Act of 2026. That argument has a surface plausibility that dissolves on closer inspection. The CAA reforms require retrospective disclosure of drug spending and utilization data. The DOL rule requires prospective disclosure of compensation arrangements before and during contract negotiations. The two serve different functions: one tells employers what happened, the other gives them the information they need to decide whether to hire or renew a PBM in the first place.

The PCMA's claim that the rule is "a solution in search of a problem" is harder to sustain when the problem has been documented by the Federal Trade Commission, multiple state attorneys general, and congressional investigations over the past several years. The FTC's 2024 report on PBM practices found that the largest PBMs were steering patients toward affiliated pharmacies, inflating drug costs for health plans, and retaining rebates that their clients believed were being passed through. The DOL rule does not break up the Big Three or restructure the market. But it does create the informational foundation that employers need to hold their PBMs accountable, and to make meaningful comparisons between competing vendors.

The Limits of Transparency as a Policy Tool

The DOL projects $22 billion in savings over a decade from the rule, a figure that reflects the agency's estimate of how much employers will be able to claw back once they can see what they are actually paying. That projection deserves some skepticism. Transparency is a necessary condition for competitive markets, but it is not a sufficient one. The Big Three's 80 percent market share means that most large employers have limited practical alternatives when negotiating PBM contracts, regardless of how much information they now have access to. Knowing that your PBM is retaining a large spread does not automatically give you the leverage to demand otherwise if the competitive alternatives are thin.

What the rule does accomplish is shift the burden of proof. PBMs will no longer be able to rely on opacity as a business model. Employers who discover through the new disclosures that their PBM is retaining rebates that were implicitly understood to be passed through will have both the documentation and the contractual mechanism to act on that information. Greg Baker, CEO of Affirmed Rx, a transparent PBM, put it plainly: "Anybody who fights this rule has something to hide." That framing is pointed, but it captures something real about what the resistance to disclosure reveals about the industry's current practices.

The rule takes effect in July 2027. The legal challenges from PBM industry groups are likely to follow. Whether the DOL's authority to impose these requirements survives judicial scrutiny will determine whether the transparency it promises actually reaches employers and their workers. But the direction of travel is clear, and for an industry that has operated in the shadows of the pharmaceutical supply chain for decades, the light is coming.